More payers are trying to rein in the use of antipsychotics in patients WITHOUT psychotic disorders
More payers are trying to rein in the use of antipsychotics in patients WITHOUT psychotic disorders.
Almost $6 BILLION a year is spent on Abilify alone.
Now the Choosing Wisely report and others are pointing out when the risks of antipsychotics are likely to outweigh their benefit.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote